Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of subcutaneous vs intravenous daratumumab
2017-000206-38Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Pharmacokinetics of Dara-SC and Dara-IV and Immunogenicity of Dara-SC and Dara-IV. Started Aug 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-000206-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000206-38.